This visible progress is a robust motivator to continue the weight loss plan, reinforcing the choice to embark on this journey??.The drug semaglutide accounted for an estimated 88% of latest GLP-one prescriptions prepared in 2023 and reviewed by the researchers. The researchers cautioned that expanding utilization of GLP-1s to take care of obesity